Short Interest in Finch Therapeutics Group, Inc. (NASDAQ:FNCH) Increases By 383.3%

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) was the target of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 11,600 shares, a growth of 383.3% from the February 29th total of 2,400 shares. Based on an average daily volume of 19,000 shares, the days-to-cover ratio is currently 0.6 days. Approximately 2.2% of the shares of the company are sold short.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. increased its holdings in Finch Therapeutics Group by 2.3% in the first quarter. BlackRock Inc. now owns 404,931 shares of the company’s stock worth $2,038,000 after purchasing an additional 9,149 shares in the last quarter. Renaissance Technologies LLC boosted its position in Finch Therapeutics Group by 202.7% in the fourth quarter. Renaissance Technologies LLC now owns 122,900 shares of the company’s stock worth $59,000 after purchasing an additional 82,300 shares during the last quarter. Millennium Management LLC purchased a new position in shares of Finch Therapeutics Group during the 2nd quarter valued at $259,000. Vanguard Group Inc. lifted its position in shares of Finch Therapeutics Group by 10.0% during the 3rd quarter. Vanguard Group Inc. now owns 35,939 shares of the company’s stock valued at $186,000 after buying an additional 3,263 shares during the last quarter. Finally, Goldman Sachs Group Inc. purchased a new stake in Finch Therapeutics Group during the 2nd quarter worth about $98,000. Institutional investors own 21.77% of the company’s stock.

Finch Therapeutics Group Stock Up 7.4 %

Shares of Finch Therapeutics Group stock opened at $2.84 on Thursday. The business has a fifty day simple moving average of $2.66 and a two-hundred day simple moving average of $3.61. Finch Therapeutics Group has a 1 year low of $2.19 and a 1 year high of $16.74.

Finch Therapeutics Group (NASDAQ:FNCH) last posted its quarterly earnings data on Monday, March 25th. The company reported ($1.89) earnings per share for the quarter.

Finch Therapeutics Group Company Profile

Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease.